Effect of Dexmedetomidine Infusion on Post Anesthesia Discharge Time
NCT ID: NCT07180810
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
82 participants
INTERVENTIONAL
2023-09-05
2025-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia
NCT02675049
The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery
NCT04454515
Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro
NCT03108937
Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Study
NCT07184125
The Effect of Dexmedetomidine of the Immune System
NCT01692210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A, receiving low dose dexmedetomidine infusion
Group A, receiving low dose dexmedetomidine infusion at 0.6mcg/kg/hour rate
Dexmedetomidine infusion low dose
low dose dexmedetomidine infusion at rate 0.6mcg/kg/hour rate .
Group B, receiving normal saline infusion as placebo
normal saline being used as placebo at rate 0.6mch/kg/hour rate
Group B receiving normal saline
Normal saline infusion at rate 0.6mcg/kr/hour rate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine infusion low dose
low dose dexmedetomidine infusion at rate 0.6mcg/kg/hour rate .
Group B receiving normal saline
Normal saline infusion at rate 0.6mcg/kr/hour rate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaukat Khanum Memorial Cancer Hospital & Research Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Almas nil Iqbal, FRCA
Role: STUDY_CHAIR
Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shaukat Khanum Memorial Cancer Hospital and Research Centre
Lahore, Pubjab, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Reference study from which sample size was calculated
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-23-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.